Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 14.08.2025 | Item 4.02 — Bilanzkorrekturen | EXTREM | SEC | ttee have discussed the matters described in this Item 4.02 with its independent registered public accounting firm, Delo |
| 13.11.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 04.09.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 15.03.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 3(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment o |
| 15.12.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ement Agreement with Mr. Chardon are described in Item 5.02 below. Also on December 12, 2023, Mr. Chardon, Benoit Char |
Stammdaten
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company is headquartered in Natick, Massachusetts.
Unternehmen & Branche
| Name | ALLURION TECHNOLOGIES, INC. |
|---|---|
| Ticker | ALUR |
| CIK | 0001964979 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Devices |
| SIC | 3841 · Surgical & Medical Instruments & Apparatus |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 5,2 Mio. USD |
| Beta | -0,25 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 15,230,000 | -28,755,000 | -3.81 | 15,772,000 | -77,189,000 |
| 2025-09-30 | 10-Q | 2,658,000 | -11,884,000 | -1.53 | 18,141,000 | -82,928,000 |
| 2025-06-30 | 10-Q | 3,379,000 | -9,335,000 | -1.28 | 28,169,000 | -63,976,000 |
| 2025-03-31 | 10-Q | 5,580,000 | -1,501,000 | 0.20 | 38,414,000 | -69,790,000 |
| 2024-12-31 | 10-K | 32,110,000 | -7,198,000 | -3.20 | 32,813,000 | -77,978,000 |
| 2024-09-30 | 10-Q | 5,367,000 | 8,736,000 | 3.40 | 50,699,000 | -64,790,000 |
| 2024-06-30 | 10-Q | 11,766,000 | -8,322,000 | -4.34 | 46,550,000 | -70,582,000 |
| 2024-03-31 | 10-Q | 9,386,000 | 1,996,000 | 2.78 | 59,988,000 | -66,162,000 |
| 2023-12-31 | 10-K | 53,467,000 | -80,607,000 | -57.83 | 71,712,000 | -71,297,000 |
| 2023-09-30 | 10-Q | 18,200,000 | -21,630,000 | -0.54 | 120,688,000 | -52,756,000 |
| 2023-06-30 | 10-Q | 12,960,000 | -21,996,000 | -0.84 | 52,151,000 | -71,218,000 |
| 2023-03-31 | 10-Q | 14,071,000 | -17,801,000 | -0.68 | -49,657,000 | |
| 2022-12-31 | 10-K | 64,211,000 | -37,744,000 | -1.51 | 51,370,000 | -32,314,000 |
| 2022-09-30 | 10-Q | 16,064,000 | -13,572,000 | -0.53 | -20,173,000 | |
| 2022-06-30 | 10-Q | 16,250,000 | -5,405,000 | -0.82 | -6,706,000 | |
| 2022-03-31 | 10-Q | -6,419,000 | -1,446,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-12-04 | Davin Michael R | Director | Open Market Sale | -1,606 | 1.58 | -2,540.85 | -25,9% | |
| 2025-12-03 | Davin Michael R | Director | Open Market Sale | -1,606 | 1.48 | -2,376.88 | -24,3% | |
| 2025-05-19 | Gaur Shantanu | Director, Officer, Chief Executive Officer | Open Market Purchase | 8,000 | 3.06 | 24,484.00 | +249,8% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.